BEONE MEDICINES (06160.HK) An Taisite Approved in Mainland China for Second-line Treatment of Small Cell Lung Cancer

News Sharing

For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields

Receiver*

Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com

Your email address*

Content Sharing

BEONE MEDICINES (06160.HK) An Taisite Approved in Mainland China for Second-line Treatment of Small Cell Lung Cancer

BEONE MEDICINES (06160.HK) announced that An Taisite (tarlatamab for injection), the first and currently only approved DLL3- and CD3-targeted bispecific T-cell engager (TCE) antibo...

Reset

Send

The window will close in 5 seconds

BEONE MEDICINES (06160.HK) An Taisite Approved in Mainland China for Second-line Treatment of Small Cell Lung Cancer

Recommend

Positive

Negative

SHORT SELL

STOCK INFO

aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

BEONE MEDICINES (06160.HK) +0.100 (+0.061%) Short selling $417.64M; Ratio 20.614% announced that An Taisite (tarlatamab for injection), the first and currently only approved DLL3- and CD3-targeted bispecific T-cell engager (TCE) antibody jointly developed and commercialized in Mainland China by the company and Amgen, has been approved by the National Medical Products Administration (NMPA). The drug is indicated for adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have previously failed one prior systemic therapy (including platinum-based chemotherapy), as a second-line treatment. (su/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-08 16:25.)

Related NewsUOB Kay Hian Adds COWELL, NTES-S to Buy List, Recommends Buying on Pullbacks

Auto-translated by AI

View Original Text

This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News

Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.